Ibrance Slows Progression of Double-Positive Metastatic Breast Cancer
When added to standard first-line maintenance therapy, Ibrance (palbociclib) delayed disease progression in people with advanced hormone receptor-positive/HER2-positive breast cancer, according to results from the PATINA trial presented at the San …